Chinese ophthalmic device maker known for orthokeratology (Ortho-K) contact lenses that slow myopia progression.
Chinese ophthalmic device maker known for orthokeratology (Ortho-K) contact lenses that slow myopia progression.
Also sells intraocular lenses, the implants that replace a clouded lens in cataract surgery, to hospitals. Ortho-K lenses are paid for privately by families rather than reimbursed by insurance, and the lenses are replaced as they wear, so sales recur with each child under treatment.
In one line: A Chinese CooperVision/Paragon for myopia-control lenses.
Moat: narrow (regulatory licence, brand). Ortho-K device approvals and clinical fitting expertise limit new entrants.
Headquarters: Beijing, China · Employees: 2,331
Size Eyebright Medical Technology (Beijing) (688050.SS) is a China Health Care company (Medical Specialties) with a market value of $1.21B, the 1830th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥41.09 on 18 Nov 2026.
Performance Over six months the shares fell 16.1%, against -9.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 21.1% over the last twelve months (peer median +12.0%); the operating margin is 16.0% (peer median 11.6%).
Valuation It trades at 23.9× forward earnings against a peer median of 32.9× (6th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +40%, so the hurdle is -30 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.4 points above its cost of capital (6.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.79B | CN¥1.47B | CN¥1.40B | CN¥944M | CN¥575M |
| Revenue growth | — | +5% | +49% | +64% | — |
| Gross profit | CN¥1.20B | CN¥875M | CN¥871M | CN¥677M | CN¥460M |
| EBITDA | n/a | CN¥533M | CN¥574M | CN¥395M | CN¥284M |
| Net income | CN¥244M | CN¥268M | CN¥388M | CN¥304M | CN¥233M |
| Free cash flow | CN¥146M | CN¥256M | CN¥19.3M | -CN¥144M | CN¥428,190 |
| Capital expenditure | CN¥167M | CN¥123M | CN¥329M | CN¥370M | CN¥271M |
| Total debt | CN¥1.17B | CN¥571M | CN¥579M | CN¥390M | CN¥163M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Eyebright Medical Technology (Beijing) 688050.SS | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% |
| Cooper Companies (The) COO | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688050.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.0% | -7.5% | 9th highest of 21 |
| 6-month return | -16.1% | -9.9% | 9th lowest of 20 |
| Distance from 52-week high | -38.1% | -37.9% | 11th highest of 21 |
| Revenue growth (TTM) | +21.1% | +12.0% | 4th highest of 19 |
| Operating margin | 16.0% | 11.6% | 10th highest of 20 |
| Forward P/E | 23.9× | 32.9× | 6th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 10.3% | 10.0% | 6th least demanding of 11 |
| Growth delivered (Del g) | +40.3% | +13.2% | highest of 11 |
| Hurdle (Req g minus delivered) | -30.0 pp | -1.9 pp | 2nd least demanding of 11 |
| ROIC minus cost of capital | +1.4 pp | +0.1 pp | 8th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% | +40.3% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 35.6× | n/a | n/a |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |